Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to ...

Kyverna reported $211.7 million in cash, cash equivalents, and marketable securities as of June 30, 2025, which the Company ...

MoonLake Immunotherapeutics remains a promising clinical-stage biotech, with potentially its first FDA approval in 2026.

Parks Tacoma says that Fora Landscape Architects will also be doing schematic designs for future Phase 3 park development, ...

The cryptocurrency world is buzzing over Ruvi AI (RUVI), a rising star in the blockchain and AI sectors. With over 225 ...

Both cameras feature AI-powered Phase Hybrid Autofocus for precise subject tracking, including eyes, faces, and fast-moving ...

Live Updates Live Coverage Updates appear automatically as they are published. How CoreWeave Performed in Q1 3:00 pm ...